Get the Stockscreener App
6.44
1.74%
+0.11
Larimar Therapeutics Inc stock is currently priced at $6.44, with a 24-hour trading volume of 143.61K.
It has seen a +1.74% increased in the last 24 hours and a -10.56% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $6.21 pivot point. If it approaches the $6.50 resistance level, significant changes may occur.
Previous Close:
$6.33
Open:
$6.38
24h Volume:
143.61K
Market Cap:
$410.87M
Revenue:
-
Net Income/Loss:
$-36.95M
P/E Ratio:
-7.00
EPS:
-0.92
Net Cash Flow:
$-33.46M
1W Performance:
-1.38%
1M Performance:
-10.56%
6M Performance:
+122.07%
1Y Performance:
+42.48%
1D Range:
$6.29
$6.56
52W Range:
$2.18
$13.68
Larimar Therapeutics Inc Stock (LRMR) Company Profile
Name
Larimar Therapeutics Inc
Sector
Industry
Phone
844 511 9056
Address
Three Bala Plaza East, Suite 506, Bala Cynwyd, PA
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-19-22 | Initiated | Guggenheim | Buy |
| Feb-15-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Feb-10-21 | Initiated | JMP Securities | Mkt Outperform |
| Feb-01-21 | Initiated | William Blair | Outperform |
Larimar Therapeutics Inc Stock (LRMR) Latest News
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
GlobeNewswire Inc.
Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s Ataxia
GlobeNewswire Inc.
Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference
GlobeNewswire Inc.
Over $37M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying
Benzinga
Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
GlobeNewswire Inc.
Cisco Issues Weak Outlook, Joins Fastly, Herbalife And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Benzinga
Larimar Therapeutics Inc Stock (LRMR) Financials Data
Larimar Therapeutics Inc (LRMR) Net Income 2024
LRMR net income (TTM) was -$36.95 million for the quarter ending December 31, 2023, a -4.51% decrease year-over-year.
Larimar Therapeutics Inc (LRMR) Cash Flow 2024
LRMR recorded a free cash flow (TTM) of -$33.46 million for the quarter ending December 31, 2023, a -20.93% decrease year-over-year.
Larimar Therapeutics Inc (LRMR) Earnings per Share 2024
LRMR earnings per share (TTM) was -$0.84 for the quarter ending December 31, 2023, a +45.45% growth year-over-year.
About Larimar Therapeutics Inc
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. The company's lead compound, CTI-1601, is being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich's ataxia, a rare and progressive genetic disease. It also focuses on using its intracellular platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. The company is headquartered in Bala Cynwyd, Pennsylvania.
1.53%
3.38%
Cap:
|
Volume (24h):